Skip to main content

Table 6 Correlation analysis of antibody levels against synthetic bDIDO1, bCPSF2, and bFOXJ2 peptides with data of subjects in the Sawara Hospital cohort

From: Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke

Present disease   HD DSWMH asympt-CI TIA AIS cCI
 Sample number   188 162 18 66 351 66
 DIDO1pep-Ab level Average 3381 3523 3481 4443 4688 4347
  SD 1660 1750 2099 2576 2740 3017
P value (vs HD)   ns ns < 0.01 < 0.001 < 0.05
 FOXJ2-Ab level Average 4627 4995 4902 5794 6298 7022
  SD 1972 2232 1854 2368 3308 5646
P value (vs HD)   ns ns < 0.01 < 0.001 < 0.001
 CPSF2-Ab level Average 7322 7571 8312 11,778 8722 10,088
  SD 3415 2942 2461 16,843 3970 4240
P value (vs HD)   ns < 0.05 < 0.01 < 0.001 < 0.001
Sex   Male Female     
 Sample number   528 389     
 DIDO1pep-Ab level Average 4081 4038     
  SD 2493 2244     
P value (vs Male)    0.781     
 FOXJ2-Ab level Average 5772 5443     
  SD 3077 3084     
P value (vs male)    0.111     
 CPSF2-Ab level Average 8633 8420     
  SD 5493 6553     
P value (vs male)    0.155     
Complication   DM− DM+     
 Sample number   732 180     
 DIDO1pep-Ab level Average 4059 4047     
  SD 2469 2027     
P value (vs DM−)    0.949     
 FOXJ2-Ab level Average 5589 5763     
  SD 3104 2987     
P value (vs DM−)    0.488     
 CPSF2-Ab level Average 8319 9437     
  SD 5373 7822     
P value (vs DM−)    0.015     
Complication   HT− HT+     
 Sample number   347 565     
 DIDO1pep-Ab level Average 3830 4196     
  SD 2217 2477     
P value (vs HT−)    0.021     
 FOXJ2-Ab level Average 5093 5948     
  SD 2373 3405     
P value (vs HT−)    < 0.0001     
 CPSF2-Ab level Average 7699 9065     
  SD 6095 5804     
P value (vs HT−)    < 0.0001     
Complication   CVD− CVD+     
 Sample number   861 51     
 DIDO1pep-Ab level Average 4003 4966     
  SD 2360 2673     
P value (vs CVD−)    0.015     
 FOXJ2-Ab level Average 5559 6712     
  SD 3050 3408     
P value (vs CVD−)    0.022     
 CPSF2-Ab level Average 8499 9232     
  SD 6037 4239     
P value (vs CVD−)    0.142     
Complication   Lipidemia− Lipidemia+     
 Sample number   649 263     
 DIDO1pep-Ab level Average 4158 3806     
  SD 2497 2073     
P value (vs Lipidemia−)   0.029     
 FOXJ2-Ab level Average 5702 5428     
  SD 3171 2841     
P value (vs Lipidemia−)   0.203     
 CPSF2-Ab level Average 8146 9531     
  SD 3583 9534     
P value (vs Lipidemia−)   0.145     
Lifestyle   Non-smoker Smoker     
 Sample number   474 441     
 DIDO1pep-Ab level Average 3732 4425     
  SD 2037 2676     
P value (vs non-smoker)   < 0.0001     
 FOXJ2-Ab level Average 5192 6111     
  SD 2793 3309     
P value (vs non-smoker)   < 0.0001     
 CPSF2-Ab level Average 8214 8901     
  SD 6086 5801     
P value (vs non-smoker)   0.002     
Lifestyle   Alcohol− Alcohol+     
 Sample number   334 581     
 DIDO1pep-Ab level Average 4001 4103     
  SD 2236 2476     
P value (vs Alcohol−)    0.527     
 FOXJ2-Ab level Average 5691 5603     
  SD 3542 2793     
P value (vs Alcohol−)    0.698     
 CPSF2-Ab level Average 8559 8591     
  SD 6946 5341     
P value (vs Alcohol−)    0.361     
  1. The subjects were divided as follows: sex (male and female); presence (+) or absence (−) of complication of DM, hypertension (HT), cardiovascular disease (CVD), or dyslipidemia, and lifestyle factors (smoking and alcohol intake habits). Antibody levels (Alpha counts) were compared using the Kruskal–Wallis test (upper panel) and the Mann–Whitney U test (lower panels). Sample numbers, averages, and SDs of counts as well as P values are shown. Significant correlations (P < 0.05) are marked in bold